These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 10668347)

  • 41. The Food and Drug Administration Amendments Act and postmarketing commitments.
    Fain K; Daubresse M; Alexander GC
    JAMA; 2013 Jul; 310(2):202-4. PubMed ID: 23839755
    [No Abstract]   [Full Text] [Related]  

  • 42. The hunt for counterfeit medicine. Drugs manufactured by counterfeiters are infiltrating markets worldwide. Investigators are harnessing a variety of analytical techniques to catch as many of the fakes as they can.
    Mukhopadhyay R
    Anal Chem; 2007 Apr; 79(7):2622-7. PubMed ID: 17476727
    [No Abstract]   [Full Text] [Related]  

  • 43. Drug safety. Gaps in the safety net.
    Couzin J
    Science; 2005 Jan; 307(5707):196-8. PubMed ID: 15653480
    [No Abstract]   [Full Text] [Related]  

  • 44. [Not only observe, also publish. New potential for the old observation of application].
    Middeke M
    Dtsch Med Wochenschr; 2003 Apr; 128(16):857-8. PubMed ID: 12701029
    [No Abstract]   [Full Text] [Related]  

  • 45. The FDA's poor oversight of postmarketing studies.
    Lancet; 2009 Nov; 374(9701):1568. PubMed ID: 19897111
    [No Abstract]   [Full Text] [Related]  

  • 46. The quantification of drug risks in practice.
    Lee D; Bergman U
    WHO Reg Publ Eur Ser; 1993; 45():79-95. PubMed ID: 8442852
    [No Abstract]   [Full Text] [Related]  

  • 47. Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project.
    Coloma PM; Schuemie MJ; Trifirò G; Gini R; Herings R; Hippisley-Cox J; Mazzaglia G; Giaquinto C; Corrao G; Pedersen L; van der Lei J; Sturkenboom M;
    Pharmacoepidemiol Drug Saf; 2011 Jan; 20(1):1-11. PubMed ID: 21182150
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Withdrawing FDA approval of midodrine after marketing.
    Holtzman NA; Starfield B
    JAMA; 2011 Feb; 305(8):781-2; author reply 782. PubMed ID: 21343575
    [No Abstract]   [Full Text] [Related]  

  • 49. [GVP (Good Vigilance Practice) regulation].
    Hattori Y
    Nihon Yakurigaku Zasshi; 2012 Sep; 140(3):127-30. PubMed ID: 22975827
    [No Abstract]   [Full Text] [Related]  

  • 50. [Tolerance and safety of tramadol use. Results of international studies and data from drug surveillance].
    Cossmann M; Kohnen C; Langford R; McCartney C
    Drugs; 1997; 53 Suppl 2():50-62. PubMed ID: 9190325
    [TBL] [Abstract][Full Text] [Related]  

  • 51. "Safer, but not safe enough".
    Crombie HD
    Conn Med; 2006; 70(10):645. PubMed ID: 17190395
    [No Abstract]   [Full Text] [Related]  

  • 52. [Official experimental testing of biomedical products. Regulatory frame and importance of for quality, safety and efficacy].
    Vieths S; Seitz R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1133-8. PubMed ID: 25123139
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The rise and fall of Natrecor for congestive heart failure: implications for drug policy.
    Kesselheim AS; Fischer MA; Avorn J
    Health Aff (Millwood); 2006; 25(4):1095-102. PubMed ID: 16835191
    [TBL] [Abstract][Full Text] [Related]  

  • 54. International guidelines on post-authorisation research and surveillance. European Economic Community.
    Herbold M
    Pharmacopsychiatry; 1997 Jan; 30(1 Suppl):62-4. PubMed ID: 9035230
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Estimating national drug consumption using data at different points in the pharmaceutical supply chain.
    Cook MN
    Pharmacoepidemiol Drug Saf; 2006 Oct; 15(10):754-7. PubMed ID: 16989003
    [No Abstract]   [Full Text] [Related]  

  • 56. Postmarketing modifications in the safety labeling of the new antiepileptics.
    Buck ML; Gurka MJ; Goodkin HP
    Neurology; 2007 May; 68(18):1536-7. PubMed ID: 17470758
    [No Abstract]   [Full Text] [Related]  

  • 57. [Post-marketing surveillance].
    Offerhaus L
    Ned Tijdschr Geneeskd; 1996 Jun; 140(22):1201; author reply 1202. PubMed ID: 8692358
    [No Abstract]   [Full Text] [Related]  

  • 58. A primer of drug safety surveillance: an industry perspective. Part II: Product labeling and product knowledge.
    Allan MC
    J Pharm Technol; 1992; 8(5):198-202. PubMed ID: 10171208
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The evolving process of European combination product review, Part II.
    Donawa ME
    Med Device Technol; 2008; 19(7):26, 28-31. PubMed ID: 19133625
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Off-label or off-limits?
    Ratner M; Gura T
    Nat Biotechnol; 2008 Aug; 26(8):867-75. PubMed ID: 18688236
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.